Enigmatic biopharmaceutical startup ENYO Pharma is at the forefront of the fight against viruses. Based in the Infectiology Center of Lyonbiopôle in Lyon, France, the company has developed a unique platform for the identification of intracellular therapeutic targets and molecules, and is developing treatments against the most important viruses. ENYO Pharma has licensed several patents issued from the discoveries of its founding scientists and is currently focused on human-infecting viruses, with the first two programs dedicated to the treatment of severe and seasonal flu and chronic hepatitis B.
A Unique Platform for the Identification of Intracellular Targets
ENYO Pharma’s research and development are focused on the identification of intracellular targets and molecules to develop new therapies against viruses. The company’s unique platform allows for the identification of small molecules and biologics that can target specific virus-host interactions, such as virus entry, replication, and persistence. ENYO Pharma’s approach involves identifying novel targets by analyzing the impact of viral infections on cellular pathways and identifying the key host factors required for the virus to replicate.
Developing Treatments Against the Most Important Viruses
ENYO Pharma is developing a range of treatments against the most important human-infecting viruses. The company’s lead programs target severe and seasonal flu and chronic hepatitis B, two viruses that cause significant morbidity and mortality worldwide. ENYO Pharma’s lead compound against severe and seasonal flu is currently undergoing Phase II clinical trials, while the chronic hepatitis B program is in the preclinical development phase. The company is also exploring the development of treatments against other viral infections, including Zika virus and human cytomegalovirus.
A Talented and Experienced Team
ENYO Pharma is led by a team of experienced and passionate scientists with a track record of success in the biopharmaceutical industry. The company’s scientific advisory board includes renowned experts in virology, drug development, and clinical trials. ENYO Pharma has also established collaborations with leading research institutions and biopharmaceutical companies to accelerate the development of its pipeline. The company has raised over €60 million in funding from investors, including Sofinnova Partners and Bpifrance.
ENYO Pharma is at the forefront of the fight against viruses, developing novel treatments against the most important human-infecting viruses using a unique platform for the identification of intracellular therapeutic targets and molecules. With a talented team, extensive funding, and promising pipeline, ENYO Pharma is poised to become a global leader in anti-virals.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!